MegaRobo, a Chinese company that uses robots and AI to run life-science experiments, has raised nearly $200 million, 36Kr first reported. Oman’s sovereign wealth fund, the Oman Investment Authority, joined the round.
The company says it has raised nearly $600 million in its ten years. This round is about a third of that, by our arithmetic.
Business Pill · Vertical Integration
An evergreen Business Engineer explainer on vertical integration. It teaches the general idea only and does not discuss MegaRobo.
The key insight: MegaRobo, which uses robots and AI to run life-science experiments, raised nearly $200 million with Oman’s sovereign wealth fund, about a third of the roughly $600 million it has raised in ten years, by our arithmetic.
What Was Announced
MegaRobo announced the round on 19 November, Jiemian News reported. Existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures added to their stakes.
CMB International, Suzhou Venture and Sanjiang Merchants Group came in alongside them, per the same reports. No valuation was disclosed.
Bloomberg ran the round as “China AI Biotech Firm Raises $200 Million in Oman-Backed Round”. We could not read its article body.

The Numbers
Jiemian puts lifetime funding at about $600 million, of which the Series C was nearly $300 million. That round, in June 2022, was led by Goldman Sachs’ investing arm, GGV Capital and Asia Investment Capital, per Sinovation Ventures.
So the new round is about two-thirds the size of the Series C, by our arithmetic. Together the two account for about 83% of everything MegaRobo has raised.
According to its Hong Kong listing prospectus, cited by 36Kr, MegaRobo had RMB 1.5 billion of orders on hand as of June 2025. It filed that application in June 2025.

What the Money Buys
MegaRobo calls its Kunpeng Lab a “data factory for the life sciences industry”. 36Kr says the lab has run unmanned experiments around the clock since its first version in 2021, and is now on version 4.0.
Per 36Kr, the platform advanced 31 drug-development pipelines in seven months, and more than 200 clients have used the lab’s research services.
Chief executive Huang Yuqing told 36Kr: “What we hope to build is the infrastructure that lets this capability happen at scale.” The company says the money goes to core R&D and to expansion in Europe, North America, the Middle East and Southeast Asia.
Gulf Money in AI
Gulf sovereign funds keep showing up on AI cap tables. Yesterday we covered Saudi Arabia’s fund in Saudi PIF’s US Stock Filing Is Now 80% SpaceX, Up From 69%.
The Structural Read
As we read the figures, the round is smaller than MegaRobo’s 2022 Series C, so the news is the new sovereign backer more than the size.
As we read the company’s description, it is selling automated lab capacity as data infrastructure for drug developers, not only robots.
Huang Yuqing, MegaRobo CEO, to 36Kr
“What we hope to build is the infrastructure that lets this capability happen at scale.”
Three Implications
FOR MEGAROBO The company says the money goes to core R&D and expansion in Europe, North America, the Middle East and Southeast Asia, per 36Kr.
FOR OMAN’S OIA The Oman Investment Authority joined existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures, per Jiemian.
FOR DRUG DEVELOPERS MegaRobo says its lab advanced 31 drug-development pipelines in seven months, per 36Kr.
What Is Not Established
We have not seen a statement from the Oman Investment Authority, the size of its stake, or MegaRobo’s valuation. The round size is “nearly” $200 million in the company’s own framing.
The Bottom Line
MegaRobo’s nearly $200 million round, with Oman’s sovereign fund, is about a third of the roughly $600 million it has raised in ten years, by our arithmetic on Jiemian’s figures.
97,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. The round, investors, lifetime funding and operating figures are from 36Kr’s first report and Jiemian News, both quoting the company on 19 November; translations from Chinese are ours. The 2022 Series C leads are from Sinovation Ventures, an investor. We read Bloomberg’s headline only. The one-third, two-thirds and 83% figures are our arithmetic. Not investment advice.
Sources: 36Kr, ‘MegaRobo completes nearly $200M financing’, 19 Nov 2026 (via NetEase) · Jiemian News, MegaRobo announces new round of nearly $200M, 19 Nov 2026 (via Sina) · Bloomberg, ‘China AI Biotech Firm Raises $200 Million in Oman-Backed Round’, 19 Nov 2026 (headline) · Sinovation Ventures, ‘MegaRobo completed US$300M Series C financing’ (2022)









